78/100 · Elevated
Manufactured by Novartis Pharmaceuticals Corporation
Oxcarbazepine Adverse Events: Seizures and Psychiatric Reactions Predominate
60,018 FDA adverse event reports analyzed
Last updated: 2026-05-12
OXCARBAZEPINE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Novartis Pharmaceuticals Corporation. Based on analysis of 60,018 FDA adverse event reports, OXCARBAZEPINE has a safety score of 78 out of 100. This score indicates a relatively favorable safety profile, with fewer or less severe adverse events compared to many other tracked medications. The most commonly reported adverse reactions for OXCARBAZEPINE include DRUG INEFFECTIVE, SEIZURE, OFF LABEL USE, FATIGUE, DIZZINESS. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for OXCARBAZEPINE.
Oxcarbazepine has a safety concern score of 78 out of 100, placing it in the high concern category based on analysis of FDA adverse event data. The FDA has received approximately 60,018 adverse event reports for this medication, which is primarily manufactured by Novartis Pharmaceuticals Corporation.
The most commonly reported adverse events include Drug Ineffective, Seizure, Off Label Use. Of classified reports, 75.8% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. Seizures and psychiatric reactions are the most common adverse events reported.
Serious adverse events, particularly psychiatric issues, are prevalent. Drug interactions and ineffective drug use are also significant concerns.
Patients taking Oxcarbazepine should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Oxcarbazepine can interact with other drugs, and its use in unapproved indications is a concern. Warnings include potential for drug interactions and ineffective treatment. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Oxcarbazepine received a safety concern score of 78/100 (high concern). This is based on a 75.8% serious event ratio across 31,344 classified reports. The score accounts for 60,018 total adverse event reports and 100 distinct reaction types. This high score reflects a significant proportion of serious adverse events in the reporting data.
Adverse event reports by sex: Female: 16,765, Male: 11,696, Unknown: 103. The most frequently reported age groups are age 54 (345 reports), age 45 (341 reports), age 52 (340 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 31,344 classified reports for OXCARBAZEPINE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
Oxcarbazepine can interact with other drugs, and its use in unapproved indications is a concern. Warnings include potential for drug interactions and ineffective treatment.
If you are taking Oxcarbazepine, here are important things to know. The most commonly reported side effects include drug ineffective, seizure, off label use, fatigue, dizziness. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Patients should report any new or worsening psychiatric symptoms or seizures to their healthcare provider immediately. Follow prescribed dosages and do not alter the medication without consulting a healthcare professional. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
The FDA closely monitors adverse events for Oxcarbazepine, and healthcare providers should be vigilant about potential serious reactions, especially psychiatric issues and seizures. Regular monitoring is advised.
The FDA has received approximately 60,018 adverse event reports associated with Oxcarbazepine. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Oxcarbazepine include Drug Ineffective, Seizure, Off Label Use, Fatigue, Dizziness. By volume, the top reported reactions are: Drug Ineffective (2,868 reports), Seizure (2,805 reports), Off Label Use (1,618 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Oxcarbazepine.
Out of 31,344 classified reports, 23,772 (75.8%) were classified as serious and 7,572 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Oxcarbazepine break down by patient sex as follows: Female: 16,765, Male: 11,696, Unknown: 103. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Oxcarbazepine adverse events are: age 54: 345 reports, age 45: 341 reports, age 52: 340 reports, age 60: 328 reports, age 51: 320 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Oxcarbazepine adverse event reports is Novartis Pharmaceuticals Corporation. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Oxcarbazepine include: Convulsion, Headache, Somnolence, Nausea, Hyponatraemia. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Oxcarbazepine to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Oxcarbazepine has a safety concern score of 78 out of 100 (high concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. Seizures and psychiatric reactions are the most common adverse events reported.
Key safety signals identified in Oxcarbazepine's adverse event data include: Seizures and convulsions are frequent, with 2805 and 1463 reports respectively.. Psychiatric issues like depression, anxiety, and suicidal ideation are common, with 940, 966, and 518 reports respectively.. Drug ineffectiveness and off-label use are reported in 2868 and 1618 cases, respectively.. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Oxcarbazepine can interact with other drugs, and its use in unapproved indications is a concern. Warnings include potential for drug interactions and ineffective treatment. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Oxcarbazepine.
Patients should report any new or worsening psychiatric symptoms or seizures to their healthcare provider immediately. Follow prescribed dosages and do not alter the medication without consulting a healthcare professional.
Oxcarbazepine has 60,018 adverse event reports on file with the FDA. Serious adverse events, particularly psychiatric issues, are prevalent. The volume of reports for Oxcarbazepine reflects both the drug's usage level and the vigilance of the reporting community.
The FDA closely monitors adverse events for Oxcarbazepine, and healthcare providers should be vigilant about potential serious reactions, especially psychiatric issues and seizures. Regular monitoring is advised. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.
Explore other medications manufactured by Novartis Pharmaceuticals Corporation and compare their safety profiles:
The following drugs share commonly reported adverse reactions with OXCARBAZEPINE:
Drugs related to OXCARBAZEPINE based on therapeutic use, drug class, or shared indications: